Comparative Pharmacology
Head-to-head clinical analysis: HISTAFED versus MUCINEX D.
Peer-Reviewed Evidence
Head-to-head clinical analysis: HISTAFED versus MUCINEX D.
HISTAFED vs MUCINEX D
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
HISTAFED is a combination of pseudoephedrine, a sympathomimetic amine that acts as a decongestant by stimulating alpha-adrenergic receptors in the nasal mucosa causing vasoconstriction, and triprolidine, a first-generation antihistamine that competes with histamine for H1-receptor sites on effector cells in the gastrointestinal tract, blood vessels, and respiratory tract, thereby preventing histamine-mediated effects.
Mucinex D contains guaifenesin, which is an expectorant that increases respiratory tract fluid secretions to reduce mucus viscosity and enhance mucus clearance, and pseudoephedrine, a sympathomimetic amine that acts as a decongestant via alpha-adrenergic receptor agonism in the nasal mucosa, causing vasoconstriction and reducing nasal congestion.
60 mg orally every 4 to 6 hours as needed; maximum 360 mg per day.
Mucinex D contains guaifenesin 600 mg and pseudoephedrine 60 mg per extended-release tablet. Usual adult dose: 1 tablet orally every 12 hours, not to exceed 2 tablets in 24 hours.
None Documented
None Documented
3-4 hours for pseudoephedrine component; shorter in children (2-3 h), prolonged in renal impairment
Guaifenesin: 1 hour (short t½, requires frequent dosing). Pseudoephedrine: 5-8 hours (prolonged with alkaline urine)
Renal (approximately 65% as unchanged drug and metabolites), biliary/fecal (35%)
Guaifenesin: Renal (primarily as metabolites, <5% unchanged). Pseudoephedrine: Renal (70-90% unchanged, dependent on urine pH)
Category C
Category C
Antihistamine/Decongestant Combination
Expectorant/Decongestant Combination